Drug intelligence / Profile preview

NM1F

Development stage: Phase 1
Lead developer: Hefei TG ImmunoPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NM1F (also known as TGI-2) is a humanized IgG1 monoclonal antibody that targets PVRIG (also known as CD112 receptor or CD112R), which is expressed on cytotoxic T lymphocytes and natural killer cells. By binding to PVRIG, NM1F acts as an immune checkpoint inhibitor, potentially enhancing anti-tumor immune responses. It is being developed for the treatment of malignant cancers and is currently in early-phase clinical trials. The drug was developed by TG ImmunoPharma.

Other names: anti-PVRIG monoclonal antibody NM1F

Targets

PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)

Beyond the preview

Go deeper on NM1F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM1F.

Explore the full profile